Broxyquinoline and brobenzoxalidine suspension (Intestopan-AI 307) in childhood diarrhoea
SummaryA clinical trial of Intestopan suspension was undertaken on 413 cases of acute diarrhoea (group A) and 120 cases of chronic diarrhoea (group B). The third group C of 178 cases was treated with other drugs to have a comparative assessment of Intestopan.A satisfactory response with Intestopan was obtained in 69.1% cases as compared to 67.4% cases of group C, and 11.4% cases in group A died as compared to 21.9% of group C. The type of response in acute diarrhoea with dehydration was primarily conditioned by the degree of dehydration. The mortality in cases with severe dehydration was 55.3% and in those with moderate and mild dehydration 42.6% and 2.1% respectively. The highest incidence of satisfactory response with Intestopan therapy was in cases above the age of 18 months.A satisfactory response in the chronic diarrhoea cases (group B) on Intestopan therapy was observed in 77.8% over 12 weeks of follow up. The initial, as well as the follow up response, was not affected by the duration of diarrhoea. The satisfactory response was maximum in those above 18 months of age (86.2%) compared to those below 18 months (65.1%).No side effects with Intestopan were met with in the present trial.